Mind Medicine (MindMed) (NASDAQ: MNMD) is a clinical-stage biotechnology company focused on developing psychedelic-inspired medicines and accompanying therapeutic protocols to treat mental health disorders and substance use disorders. The company’s research emphasizes both novel small molecules and established psychedelic compounds used in controlled, clinically supervised settings, with the goal of creating safe, scalable treatments that combine pharmacology with psychotherapy.
MindMed’s activities include preclinical research, clinical trials, and the development of treatment delivery models and protocols that integrate drug administration with therapeutic support. The company pursues a portfolio approach, advancing multiple programs through Phase 1 and later-stage studies while seeking regulatory pathways to approval. Services and products under development span drug candidates, treatment regimens, and clinician-focused training and support to enable implementation in clinical settings.
MindMed operates internationally, with clinical programs and trial sites in North America and Europe, and collaborates with academic institutions, clinical research organizations and other partners to conduct its studies. The company engages with regulators and the scientific community to generate clinical evidence and to address safety, dosing, and therapeutic best practices for psychedelic-assisted interventions.
Founded to advance the scientific and clinical development of psychedelic-based therapies, MindMed is publicly traded on the Nasdaq under the ticker MNMD. Its management focuses on advancing a pipeline through clinical development toward commercialization while building the clinical and operational infrastructure needed to support eventual treatment delivery in licensed medical settings.
AI Generated. May Contain Errors.
Free MNMD Stock Alerts